Sorrento Signs an Exclusive License Agreement with Mabpharm for ACE-MAB to Treat COVID-19

Sorrento Signs an Exclusive License Agreement with Mabpharm for ACE-MAB to Treat COVID-19

Shots:

  • The companies collaborate for the clinical development and commercialization of the ACE-MAB fusion protein that binds to the spike protein of the SARS-CoV-2 virus and treats the COVID-19
  • Sorrento will be responsible for the development and commercialization of ACE-MAB in the NA and EU, while Mabpharm retains rights in the ROW, including the China and Japan
  • ACE-MAB is a bi-specific fusion protein that consists of two functional arms, with one as Ab targeting the spike protein of SARS-CoV-2 with high affinity and other is a truncated ACE2 protein targeting a different epitope of the spike protein

Click here to­ read full press release/ article | Ref: Sorrento | Image: Contract